Global Migraine Drugs Market Market Analysis, Size, Share, Trends, Demand & Forecast to 2025
By: Report Ocean
Growth of the market is driven by factors such as increasing incidences of migraine, rising female population, patent expiration and stressed lifestyle.
Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc.
Migraine therapeutics market is expected to witness advent of first in-class novel migraine drugs especially meant for patients unresponsive to triptans or ones at risk of cardiovascular disorders. Allergan's ubrogepant and Eli Lilly's Lasmiditan are one of the leading migraine drugs based on novel mechanism of action.
Market sizing Revenue in US$ Billions & CAGR for the period 2019 to 2025
Country coverage G7 Nations - The US, The UK, Germany, France, Italy, Spain & Japan
Vendor scope Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc. & Pfizer Inc.
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global migraine therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue
> Acetylcholine Inhibitors/Neurotoxins
Regional Outlook, Revenue
> North America
> Asia Pacific
Vendors Outlook, Revenue
> Eli Lilly & Company
> Teva Pharmaceutical Industries
> Alder Biopharmaceuticals
> Amgen Inc.
> AbbVie Inc.
> Pfizer Inc.
> Migraine Drug Manufacturers
> Chemical Suppliers
> End Users
> Research Professionals
> Healthcare Consultancies
> Regulatory Bodies
Key questions answered in the report
> Historical market size of migraine therapeutics from 2009 to 2018 in US$ Billions.
> Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US$ Billions.
> Revenue forecasts of major migraine therapeutics in the period 2016 to 2025 in US$ Billions.
> Regional and country of migraine therapeutics in the period 2017 to 2025 in US$ Billions.
> Market drivers, restraints and industry trends that has impact on revenue.
> Profiling of major companies with detailed analysis of major migraine therapeutics approved for marketing as well as in pipeline.
For more info visit @ https://www.reportocean.com/